Revised forecast
Fiscal year ending May 2026 · Full yearPrevious forecast published 25 June 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The reasons were the shortfall in the number of prescriptions filled due to longer prescription durations, the higher-than-forecast revenue per prescription, the consolidation of a subsidiary's results for 14 months following a change in its fiscal year-end, higher taxes and dues, M&A-related costs and financial expenses, and weaker-than-forecast performance in the merchandising and other businesses.
| Item | Details |
|---|---|
| Net Sales | ¥66,795 million → ¥69,512 million（4.1%） |
| Operating profit | ¥1,123 million → ¥979 million（△12.8％） |
| Ordinary income | ¥941 million → ¥715 million（△24.0%） |
| Profit attributable to owners of the parent | ¥266 million → ¥114 million（△57.0%） |
| Net income per share | ¥23.45 → ¥10.01 |
| Fiscal Period Covered | Fiscal year ending May 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 25 June 2025 |
| Previous-period results | Revenue: ¥63,508 million; operating profit: ¥293 million; ordinary profit: ¥136 million; loss attributable to owners of the parent: ¥367 million; earnings per share: negative ¥32.48 (fiscal year ended May 2025) |
| Reason for the revision | The reasons were the shortfall in the number of prescriptions filled due to longer prescription durations, the higher-than-forecast revenue per prescription, the consolidation of a subsidiary's results for 14 months following a change in its fiscal year-end, higher taxes and dues, M&A-related costs and financial expenses, and weaker-than-forecast performance in the merchandising and other businesses. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the dispensing pharmacy business, the number of prescriptions filled was below forecast due to longer prescription durations. However, revenue exceeded the forecast because of higher revenue per prescription and the consolidation of a subsidiary's results for 14 months following a change in its fiscal year-end. On the earnings side, results were affected by higher taxes and dues accompanying the increase in pharmaceutical sales, higher selling, general and administrative expenses due to M&A-related costs, shortfalls in the merchandising and other businesses, and higher financial expenses associated with financing for M&A activities.